Reproducibility in Science Agenda
Reproducibility 2026: Raising the Standards in Biomedical Research
Frederick National Laboratory and Hood College Symposium, June 16–18, 2026, Hood College, Frederick, MD
See agenda for the event below, this page was last updated 04.12.2026
| Tuesday, June 16, 2026 | |
|---|---|
| 5:30 pm–7 pm | Reception - Whitaker Campus Commons |
| 7 pm–7:30 pm | Introductions |
| 7:30 pm–8:30 pm | Keynote - Hodson Auditorium, Rosenstock Hall Harvey V. Fineberg, M.D., Ph.D., |
| Wednesday, June 17, 2026 | |
|---|---|
| 7:30–8 am | Networking - Hodson Auditorium, Rosenstock Hall Continental breakfast will be provided |
| 8–8:15 am | Introduction and Goals of the Meeting Leonard P. Freedman, Ph.D., Chief Science Officer, Frederick National Laboratory for Cancer Research |
| Session 1: Translating Reproducibility: The Impact of Drug Discovery | |
| 8:15–8:50 am | Drug Discovery Christopher P. Austin, M.D., Senior Vice President, Research Technologies, GSK |
| 8:50–9:25 am | Title TBA Derek Lowe, Ph.D., Director in Chemical Biology & Therapeutics, Novartis Institutes for Biomedical ResearchTitle TBA |
| 9:25–10:00 am | Validation of Alternative Methods for Use in Regulatory Submissions Rodney Rouse, D.V.M, M.B.A., Ph.D., Acting Director, Division of Applied Regulatory Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
| 10:00–10:35 am | New Approach Methodologies (NAMs) to Accelerate Clinical Trial in a Dish (CTiD) Joseph C. Wu, M.D., Ph.D., Professor & Director of the Stanford Cardiovascular Institute, Stanford & Co-Founder, Greenstone Biosciences
|
| 10:35–10:45 am | BREAK |
| 10:45–11:20 am | Reproducible Precision Functional Genomics to Support Cancer Precision Medicine Jesse Boehm, Ph.D., Principal Investigator, Koch Institute of MIT, Chief Science Officer, Break Through Cancer |
| 11:20–11:55 am | Title TBA Valda Vinson, Ph.D., Executive Editor, Science Journals |
| 12:00–1:00 pm | Lunch |
| Session 2: One Size Does Not Fit All: Issues and Progress in Distinct Research Areas (Proteins, Antibodies, Genomics, &AI) | |
| 1:00–1:35 pm | Recombinant Proteins Aled Edwards, Ph.D., Professor of Medical Genetics and Medical Biophysics, University of Toronto |
| 1:35 PM–2:10 pm | Considerations in Characterizing Antibodies for Use in Quantitative Mass Spectrometry-Based Assays Jeff Whiteaker, Ph.D., Director of Proteomics, Paulovich Lab, Fred Hutchinson Cancer Center |
| 2:10–2:45 pm | Bespoke Cell-free DNA Fragmentation in Biomarkers for Early Cancer Detection Rob Scharpf, Ph.D., Associate Professor, Johns Hopkins School of Medicine |
| 2:45–3:20 pm | Data/AI Sean Mooney, Ph.D., Director, Center for Information Technology, National Institutes of Health |
| Session 3: Breakout Sessions | |
| 3:30–5:30 pm | Six Concurrent Breakout Sessions |
| Research Antibody Characterization | |
| Richard Kahn, Ph.D. | Professor Emeritus, Department of Biochemistry, Emory University |
| Anita Bandrowski, Ph.D. | CEO, SciCrunch; Lead, RRIDs.org |
| Will Howat, Ph.D. | Vice President, Validation & Technical Quality, Abcam |
| Carl Laflamme, Ph.D. | Group Leader, Structural Genomics Consortium, Montreal Neurological Institute (McGill University) |
| Deborah Moshinsky, Ph.D. | Director of Antibody Characterization and Validation, Institute for Protein Innovation |
| Roberto Polakiewicz, Ph.D. | Chief Scientific Officer, Cell Signaling Technology |
| Douglas Houston, Ph.D. | Professor, Developmental Studies Hybridoma Bank Direction, The University of Iowa |
| Recombinant Protein Productions | |
| Carter Mitchell, Ph.D. | Chief Science Officer, Kemp Proteins |
| Oleg Brodsky, M.B.A. | Senior Principal Scientist, Pfizer |
| William Gillette, Ph.D. | Associate Principal Scientist, Qiagen |
| Caroline DeHart, Ph.D. | Group Leader, Mass Spectrometry, NCI RAS Initiative, Frederick National Laboratory for Cancer Research |
| Aled Edwards, Ph.D. | Professor of Medical Genetics and Medical Biophysics, University of Toronto |
| Ruth Saxl, Ph.D. | Senior Manager, Protein Sciences Service, The Jackson Laboratory |
| |
| Preclinical Drug Discovery | |
| G. Sitta Sittampalam, Ph.D. | Adjunct Clinical Associate Professor of Medicine, Indiana University School of Medicine |
| Madhu Lal-Nag, Ph.D. | Chief Scientific Officer, InSphero |
| Jim McGee, Ph.D., (Retired) | Senior Director, Eli Lilly and Company |
| Samarjit Patnaik, Ph.D. | Chemistry Group Leader, National Center for Advancing Translational Sciences |
| Terry Riss, Ph.D. | Global Strategic Marketing Manager, Promega Corporation |
| Thomas “TC” D.Y. Chung, Ph.D. | Director, Translational Programs Outreach, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute |
| Sarine Markossian, Ph.D. | Editor-in-Chief, Assay Guidance Manual (AGM); Lead, AGM Translational Science Resources Program, National Center for Advancing Translational Science |
| Jayme, Dahlin, M.D., Ph.D., | Associate Director/Principal Scientist, Agios Pharmaceuticals |
| Organoids and in vitro New Approach Methodologies (NAMs) | |
| Rodney Rouse,D.V.M., M.B.A., Ph.D. | Acting Director, Division of Applied Regulatory Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
| Julie Mathieu, Ph.D. | Associate Professor, Director, Ellison Stem Cell Core, Institute for Stem Cell and Regenerative Medicine, and Co-director, UW Mouse CRISPR Core, University of Washington |
| Dennis Plenker, Ph.D. | Senior Director Research & Innovation, Xilis Inc. |
| Supreet Agarwal, Ph.D. | Senior Scientific Lead, Eli Lilly and Company |
| Stella Alimperti, Ph.D. | Associate Professor, Georgetown University |
| Genomic Data from Liquid Biopsies | |
| Jim Godsey, Ph.D. | Scientific Co-Chair, BLOODPAC |
| Jeff Allen, Ph.D. | President & CEO, Friends of Cancer Research |
| Mark Sausen, Ph.D. | Senior Director, Precision Medicine Search, Evaluation & Alliances, Bristol Myers Squibb |
| Yves Konigshofer, Ph.D. | Director, Technology Development, SeraCare Life Sciences |
| AI Science Standards | |
| Arfon Smith, Ph.D. | Staff Product Manager, GitHub |
| Ron Kikinis, M.D. | B. Leonard Holman Professor of Radiology, Harvard Medical School, Founding Director, Surgical Planning Laboratory, Department of Radiology, Brigham and Women’s Hospital |
| Jayashree Kalpathy-Cramer, Ph.D. | Chief, Division of Artificial Medical Intelligence in Ophthalmology; Professor, Ophthalmology, University of Colorado |
| Wendy Cornell, Ph.D. | Manager and Strategy Lead for Algorithms and Applications, IBM Research |
| Daniel S. Katz Ph.D. | Chief Scientist, NCSA & Research Profession, Siebel School of Computing and Data Science & School of Information Sciences, University of Illinois Urbana-Champaign |
| 5:30 - 6:15 pm | Poster Session |
| 6:30 pm | Dinner for Speakers and Panelists |
| Thursday, June 18, 2026 | |
|---|---|
| 7:30–8 am | Breakfast Continental Breakfast will be provided |
| Session 4: Roadmaps to Reproducibility | |
| 8–8:40 am | Antibodies, Performance Scores and the Lawless Frontier Joshua LaBaer, M.D., Ph.D., Executive Director and Professor, School of Molecular sciences, Biodesign Institute, Arizona State University |
| 8:40–9:20 am | The NCATS Assay Guidance Manual Program: Advancing the Practice and Rigor of Preclinical Translation Sarine Markossian, Ph.D., Editor-in-Chief, Assay Guidance Manual (AGM); Lead, AGM Translational Science Resources Program, National Center for Advancing Translational Sciences |
| 9:20–9:30 am | BREAK |
| Session 5: Reporting Back: Proposed Solutions and Remaining Challenges | |
| 9:30–9:50 am | Reporting Back—Antibody Characterization Simona Colantonio, Ph.D., Director, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research |
| 9:50–10:10 am | Reporting Back—Recombinant Proteins Carissa Grose, Interim Co-Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research |
| 10:10–10:30 am | Reporting Back—Preclinical Drug Discovery Nathan P. Coussens, Ph.D., Scientific Director, Molecular Pharmacology Laboratory, Frederick National Laboratory for Cancer Research |
| 10:30–10:50 am | Reporting Back— Organoids and in vitro New Approach Methodologies (NAMs) Stephen Jones, Ph.D., Director, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research |
| 10:50–11:10 am | Reporting Back— Ensuring Consistent and Reproducible Genomic Data from Liquid Biopsies Chris Karlovich, Ph.D., Director, Molecular Characterization Program, Frederick National Laboratory for Cancer Research Biswajit Das, Ph.D., Associate Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research |
| 11:10–11:30 am | Reporting Back— Best Practices and Solutions for Mitigating the Reproducibility Crisis in AI Science Justin Kirby, Technical Director, Cancer Imaging Informatics Laboratory, Frederick National Laboratory for Cancer Research Uma Mudunuri, Ph.D., Director, Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research |
| 11:30–11:45 am | Closing Remarks Leonard P. Freedman, Ph.D., Chief Science Officer, Frederick National Laboratory for Cancer Research |
| Noon–1:00 pm | Lunch and Adjourn |
Are you ready to say Hello?
Choose a Pathway
Information will vary based on program level. Select a path to find the information you're looking for!